written on 25.06.2014

After 4-year Benicar review, FDA slaps aside heart-risk worries


After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.

Latest Reports